Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysisCéline Eldani, E. Gérard, M. Beylot‐Barry et al.|Frontiers in Oncology|2024Cited by 14
Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patientAlexandra Duplaine, S. Prey, C. Prot-Leurent et al.|Neurological Sciences|2021Cited by 9
Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic NeuropathyGaëlle Montes, S. Prey, Cécile Herran et al.|Journal of Immunotherapy|2021Cited by 8
Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 CasesM. Gra, S. Prey, M. Beylot‐Barry et al.|Journal of Immunotherapy|2023Cited by 2
Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)Madeleine Hazard, E. Gérard, Amir Khammari et al.|Journal of Neurology|2023Cited by 2